Endometriosis is a serious gynecological disease with a global incidence of 10. This disease will have a serious impact on women’s daily lives, including severe abdominal pain, massive organ bleeding, sexual behavior difficulties, infertility,even high-risk cancer progression. We discover that the karyotype variation of ribosomes is closely related to the deterioration of endometriosis. We collaborate with Hospital on human clinical trials to develop in vitro diagnostic devices that can screen early stage of Endometriosis. It can avoid unnecessary riskscosts of discovering diseases.

The MPap DNA Methylation Test is an in vitro diagnostic reagent for endometrial cancer detection. For women atover 40 years of age with abnormal uterine bleeding, the methylation status of BHLHE22CDO1 genes from conventional Pap smear, can be used as an auxiliary diagnosis of endometrial cancer. The test result provides an important triage for further invasive endometrial biopsy, which will substantially reduce the need of invasive proceduresincrease the feasibility of endometrial cancer screening in high risk populations. This is a ground breaking test.

Our system is achieved by integrating diffractiondeep learning methods, which allows high-throughput lensless imaging system to display wide rangehigh-resolution images. In addition, the developed extraction chipsprototype were verified to accurately detect the numberproportion of blood cells under low blood demand. Our system shows great potential in point-of-care blood cells monitoring for cancer patients that could reduce infection riskmortality rate, increase efficacy of chemotherapysupport precision medicine.

We have developed a low-costportable reader for thermometric lateral flow immunoassay (TLFIA) using colloidal goldlatex beads as reportersa continuous-wave green laser as the heating source. Instead of using infrared cameras, a single-element infrared sensor is employed for temperature sensing without compromising the sensitivity of the reader. The thermometric assay provides a 10× higher sensitivity than color visualizationthe results are sufficiently quantitative to support decision making in point-of-care testing for infectious diseases (such as COVID-19).

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.